The Lung Cancer Centre of Excellence Conference 2017

The scientific programme will broadly focus on the latest multidisciplinary approaches in lung cancer research.

Further details will be added as the agenda is finalised. Timings are subject to change.

Sunday 3 December 2017

13.30 - 15.30  Delegate registration

15.30 - 16.00  Conference welcome and overview of the UK lung cancer research landscape

Caroline Dive (CRUK Lung Centre, Manchester, UK)

Charles Swanton (CRUK Lung Centre, London, UK)

16.00 - 18.00  Opening keynote lectures

Professor Mark Krasnow, Stanford University, California, USA

Professor Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, Massachusetts, USA

18.00 - 19.30  Drinks reception | Exhibition viewing

Monday 4 December 2017

08.00 - 08.30  Delegate arrival and refreshments

08.30 - 10.15  Session 1: Clinical Trials

Dr Alice Shaw (Massachusetts General Hospital, Boston, USA)

Professor Enriqueta Felip (Vall d’Hebron University Hospital, Barcelona, Spain)

Professor Gary Middleton (University of Birmingham, Birmingham, UK)

10.15 - 10.45  Refreshment break and exhibition viewing

 

10.45 - 12.30  Session 2: Discovery Science and Target Identification

Dr John Maciejowski (The Rockefeller University, New York, USA)

Dr Trever Bivona (University of California, San Francisco, USA)

Dr Yinyin Yuan (The Institute of Cancer Research, London, UK)

12.30 - 14.00  Lunch | Poster session | Exhibition viewing | Networking

 

14.00 - 15.45  Session 3: Immunology

Dr Matt Hellmann (Memorial Sloan Kettering Cancer Center, New York, USA)

Dr Pamela Ohashi (Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Canada)

Professor Robert Schreiber (BJC Institute of Health at Washington University School of Medicine, St Louis, USA)

15.45 - 16.15  Refreshment break and exhibition viewing

 

16.15 - 18.00  Session 4: Radiotherapy and Radiobiology

Dr Laurie Gaspar (UC Health, Colorado, USA)

Professor Eric Deutsch (Gustave Roussy, France)

Professor Dirk De Ruysscher (Maastricht University Medical Center, Netherlands)

18.00 - 19.15  Poster session | Exhibition viewing | Networking

 

19.45  Gala dinner

Manchester Town Hall

Tuesday 5 December 2017

08.00 - 08.30  Meet the experts

08.30 - 09.15  Keynote lecture 

Professor Harry de Koning (Erasmus MC, Rotterdam, Netherlands)

Sponsored by Siemens Healthineers09.15 - 10.45  Session 5: Early Detection and Pre-Invasive Disease

Professor Pierre Massion (Vanderbilt University School of Medicine,Tennessee, USA)

Professor Avrum Spira (Boston University Medical Campus, Boston, USA)

Professor Sam Janes (University College Hospital, London, UK)

10.45 - 11.00  Refreshment break | Poster session | Exhibition viewing

 

11.00 - 12.45  Session 6: Biomarkers and Imaging

Dr Thomas Wurdinger (VUmc Cancer Center, Amsterda, Netherlands)

Professor Hugo Aerts (Dana-Farber Cancer Institute, Boston, USA)

Dr Shannon Stott (Massachusetts General Hospital, Boston, USA)

12.45 - 13.45  Lunch | Poster session | Networking

 

13.45 - 15.45  Session 7: Tumour Evolution and Heterogeneity

Professor Matthew Meyerson (Dana-Farber Cancer Institute, Boston, USA)

Dr Mariam Jamal-Hanjani (UCL Cancer Institute, UK)

Dr Nick Lane (University College London, London, UK)

15.45 - 16.00  Refreshment break

 

16.00 - 16.45  Closing keynote

Professor Julien Sage (Stanford University Medical Center, Stanford, USA))

16.45 - 17.00  Closing remarks

Caroline Dive (CRUK Lung Centre, Manchester, UK)

Charles Swanton (CRUK Lung Centre, London, UK)

Contact us

If you need more information on the event please contact us:

CRUKlungconference@cancer.org.uk

Sponsors

 

Sponsored by Nanostring
Sponsored by Siemens Healthineers
 
 
 

If you are interested in sponsorship and exhibition opportunities, please contact

Freya Parry
Cancer Research UK

Freya.Parry@cancer.org.uk
Tel +44 (0)203 469 8471

Sharon Vanloo
CRUK Lung Cancer Centre of Excellence

s.vanloo@ucl.ac.uk
+44 (0)203 796 2940

Research opportunities in lung cancer

Lung Cancer

Survival for people with lung cancer remains low which is why we've made it a strategic priority. We have a broad range of funding opportunities for researchers wanting to focus on the disease.